Opioid Addiction News and Research

RSS

Obama administration turns bright spotlight on prescription painkiller abuse

The Obama administration turned a bright spotlight on prescription painkiller abuse in April when the Office of National Drug Control Policy released a national action plan and a statement from Vice President Joe Biden.

2 Jul 2011

Biological Psychiatry publishes Omeros' PPAR-gamma addiction program

Omeros Corporation today announced that research on the PPAR-gamma agonists it is developing in its Addiction franchise has been published in the April 1, 2011 issue of the Journal of Biological Psychiatry.

7 Apr 2011

Two reports show drastic increase in opioid prescriptions in America

Two reports by addiction researchers at the University of Pennsylvania School of Medicine and the National Institute on Drug Abuse show a drastic shift in prescribing patterns impacting the magnitude of opioid substance abuse in America.

6 Apr 2011

Using buprenorphine to treat opioid-dependent pregnant women may result in healthier babies

Using buprenorphine instead of methadone — the current standard of care — to treat opioid-dependent pregnant women may result in healthier babies, suggests new findings from an international team led by Johns Hopkins researchers and published in the Dec. 9 issue of the New England Journal of Medicine.

10 Dec 2010

Titan Pharmaceuticals presents data on Probuphine Phase 3 clinical program for opioid addiction at Neuroscience Meeting

Titan Pharmaceuticals, Inc. today announced that data from its Phase 3 clinical development program for Probuphine were presented at the Society for Neuroscience Annual Meeting, being held Nov. 13-17 in San Diego.

18 Nov 2010

Titan third quarter net loss decreases to $0.4 million

Titan Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2010.

15 Nov 2010

Orexo third quarter net revenues decrease to MSEK 35.9

"During the third quarter, Abstral™ sales were 480% higher than in the same period last year. Sales of Edluar™, Orexo's sublingual zolpidem treatment for insomnia, continue to grow more strongly from a low base, with new stock being ordered for the first time since launch and generating royalty income for Orexo.

10 Nov 2010

Positive results from Alkermes combination Phase 1 study of ALKS 33 and buprenorphine for cocaine addiction

Alkermes, Inc. today announced positive topline results from a phase 1 clinical study of an investigational combination of ALKS 33, one of Alkermes' proprietary candidates, and buprenorphine, an existing medication for the treatment of opioid addiction, for the treatment of cocaine addiction.

25 Oct 2010

Omeros receives additional NIDA grant for clinical studies in Addiction program

Omeros Corporation today announced that the National Institute on Drug Abuse (NIDA) has provided an additional grant to fund clinical studies for the Company's Addiction program. This grant, which is for a total of approximately $3.6 million to be paid over a four-year period in equal amounts, will fund direct and indirect costs of Phase 2 clinical studies to be conducted by researchers at the New York State Psychiatric Institute.

14 Oct 2010

The Partnership at Drugfree.org issues statement on FDA approval of VIVITROL for opioid dependence

The U.S. Food and Drug Administration's approval of Alkermes' opioid dependence medication (VIVITROL) for the prevention of relapse to opioid dependence following opioid detoxification is positive news for families of young adults and all those who are struggling to overcome opioid addiction. Addiction, a disease of the human brain, is a chronic illness while opioid dependence is frequently characterized by relapse.

13 Oct 2010

JAMA publishes Probuphine Phase 3 clinical trial data

Titan Pharmaceuticals, Inc. today announced that data from its previously completed and announced Phase 3 randomized, placebo-controlled clinical trial of Probuphine were published in the Journal of the American Medical Association (JAMA).

13 Oct 2010

Alkermes' VIVITROL medication for treatment of opioid dependence

Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved VIVITROL(naltrexone for extended-release injectable suspension) for the prevention of relapse to opioid dependence, following opioid detoxification.

13 Oct 2010

Titan completes enrollment in Probuphine Phase 3 study for opioid addiction

Titan Pharmaceuticals, Inc. today announced that patient enrollment is now complete in the confirmatory, Phase 3 clinical study of Probuphine for the treatment of opioid addiction. This placebo and active controlled Phase 3 study is being conducted at 20 sites in the United States and the results are expected in the second quarter of 2011, about three months ahead of the original schedule.

22 Sep 2010

Alcohol addiction drug may help opioid addicts: FDA panel considers reports

A U.S. Food and Drugs Administration (FDA) panel, this Thursday agreed that a new drug Vivitrol helps alcoholics and opioid addicts kick the habit. The panel voted 11 to 2 that there was sufficient evidence from a single clinical trial that Vivitrol is effective when it comes to helping people addicted to painkillers.

17 Sep 2010

Study finds common risk factors linked with painkiller addiction

A new Geisinger study begins to unlock the puzzle of painkiller (opioid) addiction - why some people are more likely to become addicted than others. Geisinger investigators have found that patients with four common risk factors have a significantly higher risk of addiction. In addition, a history of severe drug dependence and drug abuse compounds the risk.

30 Aug 2010

Titan Pharmaceuticals second-quarter net loss increases to $1.84 million

Titan Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010.

16 Aug 2010

Titan completes 60% enrollment in confirmatory Phase 3 clinical study of Probuphine for opioid addiction

Titan Pharmaceuticals, Inc. today announced that patient enrollment is more than 60% complete in the confirmatory Phase 3 clinical study of Probuphine for the treatment of opioid addiction, and the study is expected to complete enrollment by early fourth quarter of this year, which is almost three months ahead of schedule.

3 Aug 2010

Titan Pharmaceuticals reports total revenues of $2.4M for first-quarter 2010

Titan Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010.

17 May 2010

ABMC reports 7.6% increase in first-quarter 2010 net sales

American Bio Medica Corporation announced today its financial results for the three months ended March 31, 2010.

13 May 2010

New multi-faceted treatment program for young adults addicted to opioid drugs

A multi-faceted treatment program for young adults addicted to opioid drugs was unveiled today at the National Institute on Drug Abuse's Blending Conference in Albuquerque, N.M. This eighth meeting in the series brings together researchers and clinicians so their latest findings can be immediately applied to the needs of patients and their families dealing with addictive disorders.

23 Apr 2010